Should I buy DaVita (DVA) stock or is it too late?

DaVita · Health Care · price $179

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: UBS — 66% of its targets hit on this sector (355 calls tested). It aims for $270 (+51 %), call made on July 11, 2026, maturing on July 11, 2027 (48 d ago).

The 4 reliable analysts $222+24 %

The 1 other firm $220+23 %

How to read it: the 4 reliable firms are not filtered by optimism — 4 aim above the price, 0 below, hence their $222 median. “The 1 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on DaVita

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
UBS	71 %	+18.4 %	7	$270 +51%
Deutsche Bank	75 %	+18.2 %	8	$220 +23%
B of A Securities	67 %	+3.1 %	9	$140 -22%

In short — Should you invest in DaVita? Is it too late, still worth it? Analysts are fairly positive (60% buy, median target $220, i.e. +23%), and the most reliable on DVA targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

60% of analysts rate it a buy (Buy consensus, 5 ratings) — a sign of market conviction.
Median price target $220, i.e. +23% from the current price ($179).
The most reliable firm on DVA, Barclays (100% hit rate, 2 scored calls), targets $224 (call made on August 5, 2026, maturing on August 5, 2027) (+25%) in its most recent call, and $149 (call made on October 9, 2025, maturing on October 9, 2026) (-17%) in the one coming due soonest.
Reasonable valuation (P/E ~15) relative to its sector.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 5 ratings, 2 are neutral.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on DVA

Median target $220 (+23%) · 5 ratings · Buy consensus

Strong Buy00%

Buy360%

Hold240%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in DaVita now?

We won't decide for you. The facts: 60% of analysts rate it a buy, median target $220 (+23%), and Barclays (most reliable on DVA, 100%) targets $224. Weigh that against valuation (P/E ~15). This is not personalized advice.

Is it too late to invest in DaVita?

Not according to analysts: the median target ($220) is still +23% above the current price ($179) (most reliable on DVA: Barclays, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is DaVita still worth investing in?

It depends on the gap between the price ($179) and its estimated value: analysts target $220 on median (+23%), with 60% buys (most reliable on DVA: Barclays, 100%). Cross-check with their real reliability on DVA and the cautions above. Information, not advice.

What's the main risk in buying DVA?

The consensus is not unanimous: of 5 ratings, 2 are neutral.

→ Go deeper: the full DaVita profile (consensus, analyst reliability, price target, performance).